Kemble George reported option exercise involving 24,369 shares of Sagimet Biosciences Inc. at $6.36 for $155k on Aug 14, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed Aug 17, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$154,986.84Shares × reported price
Shares traded
24,369Series A Common Stock
Price per share
$6.36Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
413,148Direct
Trade date
Aug 14, 2026Option exercise
Filed
Aug 17, 2026, 4:05 PM ET3-day reporting delay
Accession
0001193125-26-354018Code M · Transaction 332
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 14, 2026Sell350,987$10.23−$3,591,579.77Trade 333
Aug 14, 2026Option exercise326,618$6.36$2,077,290.48Trade 331
Aug 14, 2026Option exercise326,618$0.00$0Trade 334
Aug 14, 2026Option exercise24,369$0.00$0Trade 335
5 transaction rows in this filing. Joint filers share the same rows.

SGMT price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
SGMT · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −23%1w ago −13%1d ago −11%
Returns since7d −2.1%30d +0.3%90d180d1y

Footnotes in full

F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3: This option is fully vested and exercisable as of the date hereof.